Award of Innovative Technology Contract for Helicoll

Press Release: 16 Aug 2019

HELICOLL biological skin substitute product has received an Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance improvement company in the country. The contract was based on the recommendation of HELICOLL by hospital experts in this product category who serve on one of Vizient’s member-led councils.

Documented evidence shows that HELICOLL is a biological skin substitute that results in early infiltration of new blood capillaries within four to five days after application. “HELICOLL was engineered as a sub-molecular level Nano-technology based biomatrix. It provides superiority over existing products in the market in the areas of better patient care and safety as evidenced by its human clinical studies and its vast usage over several thousands of cases during the past two decades,” said Dr. S. Gunasekaran, CEO of EnColl Corporation, HELICOLL’s manufacturer.

This contract with Vizient will offer its members enhanced savings for such next-generation product. Clinicians in all healthcare settings are charged with improving the quality of care, reducing costs, and improving patient satisfaction. This is an important product available for those needing a biological skin substitute solution. HELICOLL provides effective treatment and, based on its clinical efficacy compared to other comparable products in the marketplace, is especially useful for the treatment of diabetic leg ulcers and burn wounds.

“Hospitals and providers are looking for innovations that offer unique and cumulative benefit over other products available on the market today. Our member council determined this technology met the criteria to be recognized with the Innovative Technology designation,” said Debbie Archer, of the Innovative Technology Program.

HELICOLL is a patented, bioengineered skin substitute product categorized as a regenerative biological skin graft treatment. It is non-immunogenic, biocompatible, and highly bioactive type-I collagen membrane construct. It is an advanced wound care product used surgically for the treatment of all wounds, especially those that are non-healing. Additionally, HELICOLL can be used in acute care settings to regenerate and repair tissue from various medical conditions and injuries.

About EnColl Corporation
EnColl Corporation, established in 1994, is a California corporation that develops, manufactures, and markets Type-I collagen-based products. EnColl uses its patented technology for the preparation of high purity and charge-modified collagen (U.S. Patents 5,814,328 (1998); 6,127,143 (2000) & 6,548,077 (2003)). The company’s technologies and manufacturing system yield a series of high-quality products required for various medical fields such as general and plastic surgery (healing of wounds, burns, and dermal ulcers/sores), orthopedic surgery (bone regeneration, spinal fusion), oral surgery (periodontal and dental products), and neurological injuries (brain/nerve regeneration), drug delivery, biopharmaceutical research, cosmetic, and dietary applications.

For more Information, please Contact:
S. Gunasekaran, PhD
President – CEO
EnColl Corp. 4576 Enterprise Street, Fremont, CA-94538, USA
e-mail: guna@encoll.com
Tel. 510-396-8581